terconazole
Trade name: terazol
Approved
Dec 31, 1987
Terconazole is an antifungal drug used to treat vaginal yeast infection. Terconazole may exert its antifungal activity by disrupting normal fungal cell membrane permeability. Terconazole and other triazole antifungal agents inhibit cytochrome P450 "14-alpha-demethylase" in susceptible fungi, which leads to the accumulation of lanosterol and other methylated sterols and a decrease in ergosterol concentration. Depletion of ergosterol in the membrane disrupts the structure and function of the fungal cell leading to a decrease or inhibition of fungal growth. During controlled clinical studies conducted in the United States, 521 patients with vulvovaginal candidiasis were treated with terconazole 0.4% vaginal cream. Based on comparative analyses with placebo, the adverse experiences considered most likely related to terconazole 0.4% vaginal cream were a headache and body pain. Fever and chills, vulvovaginal burning, itching, and irritation have also been reported. The adverse drug experience on terconazole most frequently causing discontinuation was vulvovaginal itching. — NCATS
Clinical trial activity
7 trials · 8 clinical orgs · 7 marketing orgs
Earliest trial started Dec 1, 2002 (NCT00803738)
Timeline
1980s
- Dec 31, 1987
Earliest FDA Approval
- Dec 31, 1987
Johnson and Johnson — NDA Secondary Org
2000s
- Apr 6, 2004
Taro Pharmaceuticals — Marketing Organization
- Oct 1, 2004
Altana — First NDA Organization
- Oct 1, 2004
Nycomed — NDA Secondary Org
- Oct 1, 2004
Fougera — NDA Secondary Org
- Oct 1, 2004
Altana — NDA Organization
- Feb 18, 2005
Fougera — Marketing Organization
- Mar 17, 2006
Perrigo — Marketing Organization
- Mar 17, 2006
Padagis Us — Marketing Organization
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2007
Johnson and Johnson — Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Cytochrome P450 51INHIBITOR
ERG11 inhibitor
Approval history
- approvedDec 31, 1987
Chemistry & pharmacology
SMILES
CC(C)N1CCN(CC1)C2=CC=C(OC[C@@H]3CO[C@](CN4C=NC=N4)(O3)C5=CC=C(Cl)C=C5Cl)C=C2- Mol. weight
- 532.462 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaTerconazole ↗
- NCATS0KJ2VE664U ↗
- ChEMBLCHEMBL1714574 ↗
- ChEMBLCHEMBL1306 ↗
Also known as
- 1-(4-((2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-(1-methylethyl)piperazine
- cilag brand of terconazole
- fungistat
- fungistat
- fungistat
- gyno-terazol
- gyno-terazol
- gyno-terazol
- janssen brand of terconazole
- ortho brand of terconazole
- panlomyc
- panlomyc
- r 42470
- r-42470
- r-42470
- r-42470
- terazol
- terazol
- terazol
- terazol
- terazol
- terazol
- terazol 3
- terazol 3
- terazol 7
- terazol 7
- terconazole
- terconazole
- terconazole
- terconazole
- terconazole
- terconazole
- terconazole
- terconazole
- terconazole
- terconazole
- terconazole
- terconazole
- termayazole
- triaconazole
- triaconazole
- triaconazole
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03473418 | Phase 3 | Apr 1, 2018 | Assiut University |
| NCT02308007 | Phase 3 | Jun 1, 2015 | Curatek Pharmaceuticals |
| NCT02308046 | Phase 3 | Jun 1, 2015 | Curatek Pharmaceuticals |
| NCT02180100 | Phase 4 | Aug 1, 2013 | Peking University, Shanghai Shyndec Pharmaceutical Co.,Ltd. |
| NCT01867164 | Phase 3 | Dec 1, 2007 | Johnson and Johnson |
| NCT00503542 | Early Phase 1 (Phase 1) | Feb 1, 2007 | Department of Health and Human Services, Yeshiva University |
| NCT00803738 | N/A | Dec 1, 2002 | Perrigo |
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Curatek Pharmaceuticals | For profit | 2 | 2 | 1 | 2015 |
| Assiut University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Department of Health and Human Services | Government | 1 | 1 | 1 | 2007 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2007 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Perrigo | For profit | 1 | 1 | 1 | 2002 |
| Shanghai Shyndec Pharmaceutical Co.,Ltd. | For profit | 1 | 0 | 1 | 2013 |
| Yeshiva University | Academic/Hospital | 1 | 0 | 1 | 2007 |
Marketing (9)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Altana | For profit | NDA | Oct 1, 2004 |
| Fougera | For profit | MKTG | Feb 18, 2005 |
| Fougera | For profit | NDA2 | Oct 1, 2004 |
| Johnson and Johnson | For profit | NDA2 | Dec 31, 1987 |
| Nycomed | For profit | NDA2 | Oct 1, 2004 |
| Padagis Us | For profit | MKTG | Mar 17, 2006 |
| Perrigo | For profit | MKTG | Mar 17, 2006 |
| Perrigo | For profit | SYN | Mar 17, 2006 |
| Taro Pharmaceuticals | For profit | MKTG | Apr 6, 2004 |